Get notified when PRME files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Going Concern (removed) — Substantial doubt about ability to continue as a going concern was disclosed in baseline but is absent from current filing.
Prime Medicine extends runway to 2027 after workforce cuts, faces arbitration over AATD program
Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~1 min read
Key Changes
-
high
Company faces arbitration with Beam Therapeutics over AATD program rights; adverse outcome could force program shutdown, transfer to Beam, and monetary damages. Hearing concluded, awaiting decision.
Legal Proceedings verify on EDGAR → -
high
Cash runway extended from H1 2026 to 2027 following May 2025 workforce reduction ($3.7M savings) and CGD program deprioritization ($3.8M savings), despite $5.7M in arbitration legal costs.
MD&A: Liquidity verify on EDGAR → -
high
Going concern warning removed after appearing in prior filing; company no longer discloses substantial doubt about ability to continue operations beyond one year.
Risk Factors verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (THRM 10-Q) is open in full — no account needed.
Partner
Trade PRME commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 9, 2026 · How we verify